Free Trial

GSK (GSK) Stock Forecast & Price Target

GSK logo
$43.52 +0.07 (+0.15%)
Closing price 10/7/2025 03:59 PM Eastern
Extended Trading
$43.63 +0.12 (+0.26%)
As of 04:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
1
Hold
7
Buy
0

Based on 8 Wall Street analysts who have issued ratings for GSK in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 8 analysts, 1 has given a sell rating, and 7 have given a hold rating for GSK.

Consensus Price Target

$37.38
-14.11% Downside
According to the 8 analysts' twelve-month price targets for GSK, the average price target is $37.38. The highest price target for GSK is $39.50, while the lowest price target for GSK is $35.25. The average price target represents a forecasted downside of -14.11% from the current price of $43.52.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for GSK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GSK and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GSK Analyst Ratings Over Time

TypeCurrent Forecast
10/8/24 to 10/8/25
1 Month Ago
9/8/24 to 9/8/25
3 Months Ago
7/10/24 to 7/10/25
1 Year Ago
10/9/23 to 10/8/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
3 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
2 Buy rating(s)
Hold
7 Hold rating(s)
6 Hold rating(s)
7 Hold rating(s)
4 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$37.38$37.38$37.38$50.00
Forecasted Upside-14.11% Downside-6.69% Downside-5.51% Downside31.48% Upside
Consensus RatingReduceReduceHoldModerate Buy

GSK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

GSK Stock vs. The Competition

TypeGSKMedical CompaniesS&P 500
Consensus Rating Score
1.88
2.33
2.51
Consensus RatingReduceHoldModerate Buy
Predicted Upside-14.11% Downside1,308.15% Upside170.14% Upside
News Sentiment Rating
Positive News

See Recent GSK News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/27/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingHold (C)
6/3/2025Berenberg Bank
2 of 5 stars
K. Holford
Not Rated
Reiterated RatingBuyHold
4/28/2025Hsbc Global Res
5 of 5 stars
R. Kumar
Not Rated
UpgradeStrong Sell
4/15/2025BNP Paribas
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$35.25-1.07%
2/12/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageEqual Weight
11/15/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyHold
11/12/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyHold$53.00 ➝ $39.50+8.64%
10/31/2024Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyNeutral
8/27/2024Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
8/7/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/8/2024UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyNeutral
6/24/2024Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageNeutral$47.00+6.12%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 04:17 AM ET.


Should I Buy GSK Stock? GSK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, October 6, 2025. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in GSK plc:

  • The current stock price is around $40.81, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • GSK plc reported strong quarterly earnings, with earnings per share (EPS) of $1.23, exceeding analysts' expectations, indicating robust financial performance.
  • The company has shown a year-over-year revenue increase of 1.3%, suggesting stable growth in its operations.
  • GSK plc has a high return on equity of 49.22%, reflecting effective management and profitability, which can be attractive to investors seeking strong returns.
  • Institutional investors hold 15.74% of GSK plc's stock, indicating confidence from large financial entities in the company's future prospects.

GSK
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in GSK plc for these reasons:

  • The stock has experienced fluctuations, with a 52-week high of $43.62 and a low of $31.72, indicating potential volatility that could concern risk-averse investors.
  • GSK plc has a debt-to-equity ratio of 1.07, which suggests that the company has a significant amount of debt compared to its equity, potentially increasing financial risk.
  • Despite recent earnings growth, the price-to-earnings (P/E) ratio of 18.89 may indicate that the stock is overvalued compared to its earnings, which could deter some investors.
  • Recent institutional selling, such as Ancora Advisors LLC reducing its stake by 75.6%, may signal a lack of confidence among some investors.
  • The company has a quick ratio of 0.57, which is below 1, indicating potential liquidity issues that could affect its ability to meet short-term obligations.

GSK Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for GSK is $37.38, with a high forecast of $39.50 and a low forecast of $35.25.

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There is currently 1 sell rating and 7 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" GSK shares.

According to analysts, GSK's stock has a predicted downside of -14.11% based on their 12-month stock forecasts.

GSK has been rated by research analysts at Weiss Ratings in the past 90 days.

Analysts like GSK less than other "medical" companies. The consensus rating for GSK is Reduce while the average consensus rating for "medical" companies is Hold. Learn more on how GSK compares to other companies.


This page (NYSE:GSK) was last updated on 10/8/2025 by MarketBeat.com Staff
From Our Partners